BACKGROUND: Macrophage scavenger receptors facilitate the uptake of modified low-density lipoprotein (LDL), formation of foam cells, and development of atherosclerosis. Given that proinflammatory cytokines, including IL-6, can modulate the macrophage foaming process, the aim of the present study was to determine whether the synthetic retinoic acid receptor-alpha/beta-specific agonist Am80, which is also an IL-6 inhibitor, can modulate macrophage lipid accumulation and foam cell formation. METHODS AND RESULTS: Am80 suppressed IL-6 production induced by 12-myristate 13-acetate (PMA) or angiotensin II in mouse Raw264 macrophages. It also suppressed expression of the 2 major scavenger receptors (scavenger receptor-A [SR-A] and CD36), in part by inhibiting IL-6, and inhibited macrophage foam cell formation. Systemic administration of Am80 led to reductions in the areas of atherosclerotic lesions and foam cell accumulation in the aortas of apolipoprotein E (apoE)-deficient mice and reduced serum concentrations of IL-6 and IL-1beta without affecting body weights, serum lipid profiles or IL-10 levels. CONCLUSIONS: Am80 suppresses scavenger receptor expression and macrophage foam cell formation in vitro and prevents atherogenesis in apoE-deficient mice in vivo. This suggests Am80 is a novel candidate agent that could be highly useful in the prevention and treatment of atherosclerosis.
BACKGROUND: Macrophage scavenger receptors facilitate the uptake of modified low-density lipoprotein (LDL), formation of foam cells, and development of atherosclerosis. Given that proinflammatory cytokines, including IL-6, can modulate the macrophage foaming process, the aim of the present study was to determine whether the synthetic retinoic acid receptor-alpha/beta-specific agonist Am80, which is also an IL-6 inhibitor, can modulate macrophage lipid accumulation and foam cell formation. METHODS AND RESULTS:Am80 suppressed IL-6 production induced by 12-myristate 13-acetate (PMA) or angiotensin II in mouse Raw264 macrophages. It also suppressed expression of the 2 major scavenger receptors (scavenger receptor-A [SR-A] and CD36), in part by inhibiting IL-6, and inhibited macrophage foam cell formation. Systemic administration of Am80 led to reductions in the areas of atherosclerotic lesions and foam cell accumulation in the aortas of apolipoprotein E (apoE)-deficient mice and reduced serum concentrations of IL-6 and IL-1beta without affecting body weights, serum lipid profiles or IL-10 levels. CONCLUSIONS:Am80 suppresses scavenger receptor expression and macrophage foam cell formation in vitro and prevents atherogenesis in apoE-deficient mice in vivo. This suggests Am80 is a novel candidate agent that could be highly useful in the prevention and treatment of atherosclerosis.
Authors: Kamran Anwar; Iryna Voloshyna; Michael J Littlefield; Steven E Carsons; Peter A Wirkowski; Nadia L Jaber; Andrew Sohn; Sajan Eapen; Allison B Reiss Journal: Lipids Date: 2010-12-22 Impact factor: 1.880
Authors: Olesya Krivospitskaya; Ali Ateia Elmabsout; Eva Sundman; Leif A Söderström; Olga Ovchinnikova; Andreas C Gidlöf; Nikolai Scherbak; Giuseppe Danilo Norata; Ann Samnegård; Hans Törmä; Samy M Abdel-Halim; Jan-Håkan Jansson; Per Eriksson; Allan Sirsjö; Peder S Olofsson Journal: Mol Med Date: 2012-05-09 Impact factor: 6.354
Authors: Bart Lammers; Ying Zhao; Menno Hoekstra; Reeni B Hildebrand; Dan Ye; Illiana Meurs; Theo J C Van Berkel; Miranda Van Eck Journal: PLoS One Date: 2011-10-11 Impact factor: 3.240
Authors: Anna V Zetterqvist; Lisa M Berglund; Fabiana Blanco; Eliana Garcia-Vaz; Maria Wigren; Pontus Dunér; Anna-Maria Dutius Andersson; Fong To; Peter Spegel; Jan Nilsson; Eva Bengtsson; Maria F Gomez Journal: PLoS One Date: 2013-06-03 Impact factor: 3.240